



Missouri Pharmacy Program – Preferred Drug List



Fibromyalgia Agents

Effective 06/02/2010

Revised 04/05/2018

Preferred Agents

Clinical Edits May Apply

- Duloxetine Capsules (generic Cymbalta®)
- Lyrica® Capsules

Non-Preferred Agents

Clinical Edits May Apply

- Cymbalta® Capsules
- Duloxetine Caps (generic Irenka®)
- Irenka® Capsules
- Lyrica® Solution
- Savella® Tablets

Approval Criteria

- Appropriate Diagnosis for each agent:

Therapy will be approved for the following diagnostic criteria:

Condition	Approved Drugs
Fibromyalgia	Duloxetine, Lyrica®, Savella®
Osteoarthritis	Duloxetine
Lumbago	Duloxetine
Peripheral Neuropathy associated with diabetes	Lyrica®
Postherpetic Neuralgia	Lyrica®
Partial Epilepsy	Lyrica®
Fibromyalgia	Lyrica®
Neuropathy Post Spinal Cord Injury	No available diagnosis code Clinical Consultant Approval

- Failure to achieve desired therapeutic outcomes with trial on 2 preferred agents
 - Documented trial period for preferred agents
 - Documented ADE/ADR to preferred agents
- Documented compliance on current therapy regimen

Denial Criteria

- Failure to meet approval criteria
- Concurrent use of Monoamine Oxidase Inhibitors
- Children 17 years of age and younger (Subject to Clinical Consultant Review)
- Lack of adequate trial on preferred agents
- After 90 days of Fibromyalgia Agent therapy, documentation of more than three medications from the five drug classes listed below:
 - In any combination as a treatment for fibromyalgia
- Drug Prior Authorization Hotline: (800) 392-8030

Most Common Drug Classes Concurrently used in Fibromyalgia Treatment

- Tricyclic Antidepressants (TCA)
 - Selective Serotonin Re-uptake Inhibitors (SSRI)
 - Serotonin-Norepinephrine Re-uptake Inhibitors (SNRI)
 - Antiepileptics
 - Skeletal Muscle Relaxants (e.g. Cyclobenzaprine)
 - Short-Acting Opioids*
- *Opioids are no longer recommended as first or second-line treatment due to addiction risks and adverse effects***